651eTiP CAPItana: A phase IIIb study to evaluate the use of capivasertib in combination with fulvestrant in patients with advanced breast cancer who have relapsed/progressed on endocrine therapy and CDK4/6 inhibitors reflecting real-world clinical practice in Spain NCT06764186
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), C. Saura Manich(Vall d'Hebron Hospital Universitari), C. San Millan(AstraZeneca (Spain)), Nelly Oliver(AstraZeneca (Spain)), C. Mordillo(AstraZeneca (Spain)), T. Pascual(Hospital Clínic de Barcelona), Ana Callejo(AstraZeneca (Spain)), Manuel Oliveira(Check Point (Israel)), Ildefonso Cuesta(AstraZeneca (Spain))
Cited by 0
Related Papers
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
|British Journal of Cancer|2017|106
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer
|JAMA Oncology|2024|77
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
|Nature Communications|2023|65
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
|European Journal of Surgical Oncology|2018|60
Chronic opioid therapy in long-term cancer survivors
|Clinical & Translational Oncology|2016|59